Advanced search
Publication Cover
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration Volume 24, 2023 - Issue 5-6
Submit an article Journal homepage
1,901
Views
2
CrossRef citations to date
0
Altmetric
ALS Untangled

ALSUntangled #67: rituximab

Xiaoyan Li1 Department of Neurology, Duke University, Durham, NC, USAView further author information
,
Carmel Armon2 Department of Neurology, Loma Linda University, Loma Linda, CA, USAView further author information
,
Paul Barkhaus3 Department of Neurology, Medical College of Wisconsin, Milwaukee, WI, USAView further author information
,
Benjamin Barnes4 Department of Neurology, Medical College of Georgia, Augusta, GA, USAView further author information
,
Michael Benatar5 Department of Neurology, University of Miami, Miami, FL, USAORCID Iconhttps://orcid.org/0000-0003-4241-5135View further author information
ORCID Icon,
Tulio Bertorini6 Neurology Department, University of Tennessee Health Science Center, Memphis, TN, USAView further author information
,
Mark Bromberg7 Department of Neurology, University of Utah, Salt Lake City, UT, USAView further author information
,
Gregory T. Carter8 Department of Rehabilitation, Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, USAView further author information
,
Jesse Crayle9 Neurology Department, Washington University, St. Louis, MO, USAView further author information
,
Merit Cudkowicz10 Department of Neurology, Harvard Medical School, Boston, MA, USAView further author information
,
Mazen Dimachkie11 Department of Neurology, University of Kansas, Kansas City, KS, USAView further author information
,
Eva L. Feldman12 Department of Neurology, University of Michigan, Ann Arbor, MI, USAView further author information
,
Jonathan Glass13 Department of Neurology, Emory University, Atlanta, GA, USAView further author information
,
Jill Goslinga14 Department of Neurology, University of California San Francisco, San Francisco, CA, USAView further author information
,
Terry Heiman-Patterson15 Department of Neurology, Temple Health, Philadelphia, PA, USAView further author information
,
Sartaj Jhooty16 University of North Carolina at Chapel Hill, Chapel Hill, NC, USAView further author information
,
Rachel Lichtenstein17 Avram and Stella Goren-Goldstein Biotechnology Engineering Department, Ben-Gurion University of the Negev, Beer-Sheva, IsraelView further author information
,
Isaac Lund18 Undergraduate, Green Hope High School, Cary, NC, USAView further author information
,
Christopher Mcdermott19 Department of Neuroscience, University of Sheffield, Sheffield, UKORCID Iconhttps://orcid.org/0000-0002-1269-9053View further author information
ORCID Icon,
Gary Pattee20 Department of Neurology, University of Nebraska Medical Center, Omaha, NE, USAView further author information
,
Kaitlyn Pierce21 Department of Neuroscience, University of North Carolina at Chapel Hill, Chapel Hill, NC, USAView further author information
,
Dylan Ratner22 Undergraduate, Longmeadow High School, Longmeadow, MA, USAView further author information
,
Kristiana Salmon23 Department of Neurology, Montreal Neurological Institute, Montreal, CA andView further author information
,
Paul Wicks24 Independent Consultant, Lichfield, UKORCID Iconhttps://orcid.org/0000-0002-2293-9284View further author information
ORCID Icon &
Richard Bedlack1 Department of Neurology, Duke University, Durham, NC, USACorrespondence[email protected]
View further author information
 show all
Pages 544-547 | Received 22 Jul 2022, Accepted 04 Sep 2022, Published online: 15 Sep 2022
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Abstract

ALSUntangled reviews alternative and off-label treatments on behalf of people with ALS who ask about them. Here we review rituximab, a drug which specifically depletes B lymphocytes. We show a current lack of evidence for a role of these cells in ALS progression. The one patient we found who described using Rituximab for their ALS found no benefit. Given all this, and the known serious risks of rituximab, we advise against its use as an ALS treatment.

Declaration of interest

No potential conflict of interest was reported by the author(s).

Additional information

Funding

ALSUntangled is sponsored by ALS Association [Grant 23-SI-622].

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Download PDF

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.